OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CORBF.PK58

Global Cord Blood Corp

Healthcare Facilities & ServicesVerified

Global Cord Blood Corp maintains a strong liquidity position, with a current ratio of 10.73, indicating a high ability to meet short-term obligations. The company holds CNY 6.66 billion in cash and equivalents, which is significantly higher than its total liabilities of CNY 3.66 billion, suggesting a conservative capital structure with no long-term debt. This liquidity position supports operational flexibility and reduces financial risk. In terms of profitability, the company reports a return on equity (ROE) of 10.27% and a return on assets (ROA) of 5.87%. These figures are strong and suggest efficient use of equity and assets to generate profit. The operating margin, calculated as operating income of CNY 608.87 million on revenue of CNY 1.24 billion, is approximately 49.02%, which is well above the industry median for healthcare services. The company's revenue is concentrated in a single business segment, as disclosed in its financial reporting, with no geographic diversification provided in the available data. This lack of segment and geographic diversification may expose the company to higher operational and market risks if demand in its primary market fluctuates. Looking ahead, the company is expected to maintain a stable growth trajectory, with no significant changes in revenue or earnings projected in the next fiscal year. The absence of capital expenditure and the presence of positive free cash flow of CNY 537.62 million indicate that the company is not currently investing heavily in expansion, which may limit future growth potential. The company's risk profile is characterized by low liquidity and dilution risks, with no immediate filing-based flags detected. The absence of long-term debt and the high cash reserves further support this low-risk profile. Additionally, the dilution potential is low, with no recent issuance or shelf registration activity reported. Recent filings and transcripts do not indicate any material events or strategic shifts. The company's ESG governance score of 55.9 and social score of 34.5 suggest moderate governance performance and room for improvement in social responsibility practices.

30-day price · CORBF.PK-0.15 (-13.6%)
Low$0.95High$1.10Close$0.95As of13 May, 00:00 UTC
Profile
CompanyGlobal Cord Blood Corp
TickerCORBF.PK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Global Cord Blood Corp operates in the healthcare facilities and services industry, specializing in biotechnology, particularly in the collection, processing, and storage of cord blood for medical use.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Services & Equipment business sector, with a confidence level of 0.92 according to verified market data.

Global Cord Blood Corp maintains a strong liquidity position, with a current ratio of 10.73, indicating a high ability to meet short-term obligations. The company holds CNY 6.66 billion in cash and equivalents, which is significantly higher than its total liabilities of CNY 3.66 billion, suggesting a conservative capital structure with no long-term debt. This liquidity position supports operational flexibility and reduces financial risk. In terms of profitability, the company reports a return on equity (ROE) of 10.27% and a return on assets (ROA) of 5.87%. These figures are strong and suggest efficient use of equity and assets to generate profit. The operating margin, calculated as operating income of CNY 608.87 million on revenue of CNY 1.24 billion, is approximately 49.02%, which is well above the industry median for healthcare services. The company's revenue is concentrated in a single business segment, as disclosed in its financial reporting, with no geographic diversification provided in the available data. This lack of segment and geographic diversification may expose the company to higher operational and market risks if demand in its primary market fluctuates. Looking ahead, the company is expected to maintain a stable growth trajectory, with no significant changes in revenue or earnings projected in the next fiscal year. The absence of capital expenditure and the presence of positive free cash flow of CNY 537.62 million indicate that the company is not currently investing heavily in expansion, which may limit future growth potential. The company's risk profile is characterized by low liquidity and dilution risks, with no immediate filing-based flags detected. The absence of long-term debt and the high cash reserves further support this low-risk profile. Additionally, the dilution potential is low, with no recent issuance or shelf registration activity reported. Recent filings and transcripts do not indicate any material events or strategic shifts. The company's ESG governance score of 55.9 and social score of 34.5 suggest moderate governance performance and room for improvement in social responsibility practices.
Key takeaways
  • Global Cord Blood Corp has a strong liquidity position with a current ratio of 10.73 and no long-term debt.
  • The company demonstrates high profitability with a 49.02% operating margin and ROE of 10.27%.
  • Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
  • The company is not currently investing in expansion, as indicated by minimal capital expenditures.
  • The company has a low risk profile with no immediate liquidity or dilution concerns.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$1.24B
Gross profit$1.06B
Operating income$608.9M
Net income$501.1M
R&D
SG&A
D&A
SBC
Operating cash flow$613.6M
CapEx-$19.8M
Free cash flow$537.6M
Total assets$8.53B
Total liabilities$3.66B
Total equity$4.88B
Cash & equivalents$6.66B
Long-term debt$0.00
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$4.88B
Net cash$6.66B
Current ratio10.7
Debt/Equity0.0
ROA5.9%
ROE10.3%
Cash conversion1.2%
CapEx/Revenue-1.6%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
MetricCORBF.PKActivity
Op margin49.0%11.5% medp25 9.9% · p75 15.0%top quartile
Net margin40.3%8.6% medp25 6.3% · p75 12.4%top quartile
Gross margin85.3%28.8% medp25 28.8% · p75 28.8%top quartile
CapEx / revenue-1.6%4.2% medp25 3.8% · p75 4.2%bottom quartile
Debt / equity0.0%71.3% medp25 60.7% · p75 71.3%bottom quartile
Observations
IR observations
Last actual EPS0.32 CNY
Last actual revenue149,343,000 CNY
market data ESG controversies score23.1
market data ESG governance pillar55.9
market data ESG social pillar34.5
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 14:06 UTC#41918d04
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 14:09 UTCJob: 9b15666f